227. Osler disease Clinical trials / Disease details

Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03954782 (ClinicalTrials.gov)	June 22, 2020	15/5/2019	Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.	Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study	Telangiectasia, Hereditary Hemorrhagic;Rendu Osler Disease	Drug: Nintedanib 150 mg and 100 mg soft capsules;Drug: Oral treatment of placebo soft capsule	Hospices Civils de Lyon	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	France
2	EUCTR2019-002593-31-FR (EUCTR)	05/11/2019	05/09/2019	Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICURE	Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseA national, randomized, multicenter phase II studyEPICURE	Hereditary Hemorrhagic Telangiectasia MedDRA version: 20.1;Level: LLT;Classification code 10019887;Term: Hereditary hemorrhagic telangiectasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: OFEV Product Name: nintédanib Other descriptive name: NINTEDANIB	Hospices Civils de Lyon	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	France